Hematology Patient Recruitment Built for Complex Protocols and Hard-to-Reach Populations
Hematology patient recruitment fails for consistent reasons. Patient pools are smaller, diagnoses are often delayed or miscoded, and eligibility can hinge on lab values, prior lines of therapy, genotype, transfusion history, or anticoagulation status. Many eligible patients do not learn about a study until they have already started a disqualifying therapy or their lab window has moved.
Sickle cell disease is a clear example. Enrollment remains low, and the barrier is rarely site effort alone. It is reach, trust, and logistics across a dispersed population with high day to day burden.
Patiro plans recruitment around those constraints. We map protocol critical inclusion and exclusion criteria up front and build a pre-screener that captures the data sites need to qualify patients. Outreach focuses on the channels hematology patients use, including community and advocacy pathways when historical mistrust and access barriers affect participation.
Patiro's Expertise in Hematology Patient Recruitment
Hematology protocols often see late disqualifiers. Lab thresholds, transfusion dates, cytogenetics, prior therapies, and concomitant meds can push screen failure rates up when they are confirmed only after a site visit. Patiro collects these data earlier, triages candidates faster, and sends sites candidates who are more likely to qualify and attend.
Our teams have supported recruitment across hematology and hemato-oncology indications, including B-cell malignancies, Follicular Lymphoma, Polycythemia Vera, Myelofibrosis, and MDS among others. We also support studies in indications with similar recruitment constraints such as high visit burden, fatigue, comorbidities, and retention risk.
Why Partner With Patiro for Your Hematology Patient Recruitment?
Patiro runs recruitment as a full service program or as FSP support, depending on your site footprint and where enrollment risk sits. We align recruitment operations to the protocol, not to a generic referral volume target.
Commercial terms can be set as pay per enrolled patient so spend tracks enrollment outcomes. Sponsors get active visibility into recruitment and site performance as enrollment progresses.
Retention risk is planned early, not after the first missed visit. When fatigue, caregiver burden, infusion schedules, or travel distance will drive drop off, we build lower burden paths that can include phone pre-screening, travel support, and home visits for select assessments when the protocol and local requirements permit.
Frequently Asked Questions
How does Patiro reduce screen failures in a hematology trial?
We pre-screen early against protocol critical criteria and collect key details before a site visit, so sites spend time on candidates with a higher likelihood of enrollment.
Can you reach rare and geographically dispersed patients?
Yes. We use targeted digital outreach and community and advocacy channels, then expand geography when incidence around sites is not sufficient.
How do you support patients who live far from research sites?
We reduce burden where feasible through phone screening, travel coordination, and home visits for select activities when allowed by the protocol and local rules.
How does pricing work?
Patiro offers a pay-per-enrolled-patient model, meaning sponsors pay for enrolled participants rather than referral volume. This keeps budget risk low and aligns Patiro's incentives directly with the sponsor's enrollment goals.
How fast can you start hematology patient recruitment?
Launch timing depends on protocol clarity, geographies, and the site plan. Patiro can mobilise quickly once pre-screening and referral pathways are confirmed. With experience supporting rescue studies where enrollment had already fallen behind, Patiro knows how to move fast without compromising referral quality
